다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
영국
LSE
Sandoz Group Ag (0SAN)
Sandoz Group Ag (0SAN) 뉴스

0SAN

Sandoz (0SAN)

Sandoz Group Ag

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:LSE:0SAN

1

일자	시간	출처	헤드라인	심볼	기업
2024/05/22	14:00	UK Regulatory	Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe	LSE:0SAN	Sandoz Group Ag
2024/05/07	14:00	UK Regulatory	Sandoz reports first quarter 2024 sales	LSE:0SAN	Sandoz Group Ag
2024/04/30	19:25	UK Regulatory	Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG	LSE:0SAN	Sandoz Group Ag
2024/04/30	14:00	UK Regulatory	Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars	LSE:0SAN	Sandoz Group Ag
2024/04/22	14:00	UK Regulatory	Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering	LSE:0SAN	Sandoz Group Ag
2024/03/21	22:00	UK Regulatory	Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines	LSE:0SAN	Sandoz Group Ag
2024/03/13	15:00	UK Regulatory	Sandoz reports fourth quarter 2023 sales and full-year 2023 results	LSE:0SAN	Sandoz Group Ag
2024/03/06	03:24	UK Regulatory	Sandoz receives FDA approval for first and only denosumab biosimilars	LSE:0SAN	Sandoz Group Ag
2024/03/05	15:00	UK Regulatory	Sandoz announces nominations to the Board of Directors and leadership change	LSE:0SAN	Sandoz Group Ag
2024/03/04	15:00	UK Regulatory	Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market	LSE:0SAN	Sandoz Group Ag
2024/02/29	15:00	UK Regulatory	Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs	LSE:0SAN	Sandoz Group Ag
2024/02/01	15:15	UK Regulatory	Sandoz announces changes in the Board of Directors	LSE:0SAN	Sandoz Group Ag
2024/01/31	15:00	UK Regulatory	Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany	LSE:0SAN	Sandoz Group Ag

검색 관련기사 보기:LSE:0SAN

1

United Utilities

Blitzen Sec.62d

Bos(shd)n2.a-bk

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관